Sanofi's RIPK1 Inhibitor SAR443122 Granted Clinical Trial Approval in China for Ulcerative Colitis

On March 20, the CDE website showed that Sanofi's SAR443122 (eclitasertib, DNL758) was approved for clinical trials, with the indication being ulcerative colitis.

SAR443122 is a selective receptor-interacting serine/threonine-protein kinase 1 (RIPK1) small molecule inhibitor. In October 2018, Sanofi and Denali reached a global development and commercialization collaboration for two RIPK1 inhibitors, SAR443122 and SAR443820 (DNL788).

RIPK1 is a key signaling protein in the tumor necrosis factor (TNF) receptor signaling pathway, regulating inflammation and cell death in tissues throughout the body. Studies have shown that increased RIPK1 activity in the brain drives neuroinflammation and programmed necrosis, and is associated with various central nervous system (CNS) and peripheral diseases.

RIPK1 Inhibitor Entering Phase II Clinical Trials

(Source: PharmaCube NextPharma Database)

Currently, no RIPK1 inhibitors have been approved for marketing globally, and there are six products that have entered Phase II clinical trials. Among them, GFH312 from China's Jinfang Pharmaceuticals has also entered Phase II clinical trials, with an indication for intermittent claudication.

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article; if you need to reprint, please leave a message to the WeChat Official Account backend or send a message, and include the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

PharmaCube Reader Survey Questionnaire

Thank you for your companionship. Looking forward to your feedback.

Scan the QR code to provide valuable suggestions